We are live on
!
Find out more
RSCM
Rock Springs Capital Management Portfolio holdings
AUM
$1.7B
1-Year Est. Return
93.03%
This Fund
S&P 500
This Quarter
Est. Return
+50.39%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$3.65B
AUM Growth
+$1.23B
(+51%)
Cap. Flow
+$333M
Cap. Flow
% of AUM
9.14%
Top 10 Holdings %
Top 10 Hldgs %
23.51%
Holding
147
New
14
Increased
82
Reduced
11
Closed
4
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Centene
CNC
|
+$36.8M |
| 2 |
UnitedHealth
UNH
|
+$30.1M |
| 3 |
Royalty Pharma
RPRX
|
+$24.7M |
| 4 |
Novavax
NVAX
|
+$21.8M |
| 5 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$19.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
FTSV
Forty Seven, Inc. Common Stock
FTSV
|
+$42.7M |
| 2 |
Intuitive Surgical
ISRG
|
+$17.5M |
| 3 |
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
|
+$6.7M |
| 4 |
Ultragenyx Pharmaceutical
RARE
|
+$6.68M |
| 5 |
Thermo Fisher Scientific
TMO
|
+$4.96M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 92.16% |
| 2 | Consumer Staples | 1.09% |
| 3 | Consumer Discretionary | 0.54% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Neurocrine Biosciences
NBIX
$18.7B
| $167M | 4.57% |
1,366,500
+17,000
| +1% | +$1.88M |
|
|
2
UnitedHealth
UNH
$383B
| $119M | 3.28% |
405,000
+105,000
| +35% | +$30.1M |
|
|
3
Centene
CNC
$30.1B
| $83.6M | 2.29% |
1,315,000
+565,000
| +75% | +$36.8M |
|
4
iRhythm Holdings
IRTC
$3.91B
| $75.4M | 2.07% |
651,000
+6,000
| +0.9% | +$662K |
|
|
BPMC
5
DELISTED
Blueprint Medicines
BPMC
| $74.9M | 2.05% |
960,029
+223,029
| +30% | +$15.1M |
|
6
Humana
HUM
$44B
| $74.1M | 2.03% |
191,000
+33,500
| +21% | +$12.5M |
|
|
7
Intuitive Surgical
ISRG
$126B
| $68.4M | 1.88% |
360,000
-97,500
| -21% | -$17.5M |
|
8
Zai Lab
ZLAB
$2.06B
| $66.8M | 1.83% |
813,246
+63,246
| +8% | +$4.28M |
|
9
argenx
ARGX
$54.6B
| $64.8M | 1.78% |
287,500
+40,000
| +16% | +$7.1M |
|
10
Agios Pharmaceuticals
AGIO
$1.95B
| $63.1M | 1.73% |
1,179,720
+124,220
| +12% | +$5.75M |
|
|
IMMU
11
DELISTED
Immunomedics Inc
IMMU
| $59.5M | 1.63% |
1,677,679
+627,679
| +60% | +$18.4M |
|
12
Insulet
PODD
$11.5B
| $56.9M | 1.56% |
293,000
+1,000
| +0.3% | +$191K |
|
13
Baxter International
BAX
$13.8B
| $55.5M | 1.52% |
645,000
| – | – |
|
14
Sarepta Therapeutics
SRPT
$1.64B
| $55.4M | 1.52% |
345,500
| – | – |
|
15
HCA Healthcare
HCA
$85.7B
| $53.3M | 1.46% |
549,500
+29,500
| +6% | +$3.07M |
|
16
Encompass Health
EHC
$11B
| $51.6M | 1.41% |
1,046,453
+21,998
| +2% | +$1.19M |
|
17
Acadia Pharmaceuticals
ACAD
$4.55B
| $51.1M | 1.4% |
1,055,000
+30,000
| +3% | +$1.44M |
|
18
Alnylam Pharmaceuticals
ALNY
$27.4B
| $51.1M | 1.4% |
345,000
-36,500
| -10% | -$4.92M |
|
|
19
Ultragenyx Pharmaceutical
RARE
$2.56B
| $50.6M | 1.39% |
646,841
-100,959
| -14% | -$6.68M |
|
20
Pacira BioSciences
PCRX
$1.06B
| $48.5M | 1.33% |
925,000
+25,000
| +3% | +$1.04M |
|
21
Biogen
BIIB
$30.7B
| $48.2M | 1.32% |
180,000
| – | – |
|
22
BioMarin Pharmaceuticals
BMRN
$11.7B
| $47.8M | 1.31% |
387,500
+7,500
| +2% | +$745K |
|
|
23
Novavax
NVAX
$1.22B
| $47.6M | 1.3% |
+570,598
| New | +$21.8M |
|
24
Teleflex
TFX
$5.86B
| $47.3M | 1.3% |
130,000
| – | – |
|
|
NVRO
25
DELISTED
NEVRO CORP.
NVRO
| $46.1M | 1.26% |
386,000
+40,000
| +12% | +$4.74M |
|
Similar funds
AAM
SGI
ACM
BCM
ISS
PP
FDP
GAM
Rock Springs Capital Management's Q2 2020 Portfolio in Review
As of Q2 2020, Rock Springs Capital Management held 147 positions worth $3.65B, up 51% from $2.42B the previous quarter. Its ten largest holdings account for 24% of the portfolio.
Rock Springs Capital Management deployed $333M of net new capital in Q2 2020, opening 14 new positions and adding to 82 existing holdings. Its largest new stake was Royalty Pharma: 500,000 shares worth $24.3M.
By sector, the portfolio is most concentrated in Healthcare at 92% of assets, down from 95% a quarter earlier, followed by Consumer Staples and Consumer Discretionary.
On the sell side, the largest reduction was Intuitive Surgical, an estimated $17.5M trimmed.
- Rock Springs Capital Management's largest Q2 2020 buy was Royalty Pharma: 500,000 shares worth $24.3M.
- Rock Springs Capital Management added most to Centene in Q2 2020, an estimated $36.8M increase.
- Rock Springs Capital Management's biggest Q2 2020 reduction was Intuitive Surgical, cutting an estimated $17.5M.
- Rock Springs Capital Management fully exited Forty Seven, Inc. Common Stock in Q2 2020, selling an estimated $42.7M.
- Rock Springs Capital Management's ten largest holdings make up 24% of its $3.65B portfolio in Q2 2020.
- Rock Springs Capital Management opened 14 new positions and closed 4 in Q2 2020.
- Rock Springs Capital Management's portfolio value rose 51% quarter-over-quarter to $3.65B.
Based on Rock Springs Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.